Cognition and Memory Enhancement Drugs: Technologies and Global Markets
REPORT SCOPE
This research report presents an in-depth analysis of the global cognition and memory-enhancing drugs market by application, product categories, and regional markets. The report includes key cognition drugs that are incorporated in several therapeutic treatment methods. It discusses the role of supply chain members from manufacturers to researchers. The report has an in-depth analysis of key companies operating in the global cognition and memory-enhancing drugs market. In-depth patent analysis in the report will focus on providing extensive technological trends across years and regions such as the U.S., Europe, and China.
The cognition and memory-enhancing drugs market is segmented mainly into eight components: Aricept, Exelon, Reminyl, Namenda, Adderall, Ritalin, Dexedrin, and other cognition drugs. This market is further segmented on the basis of applications, which helps in understanding the potency of these memory enhancers in several therapeutic treatments. The market study is detailed for products based on applications as well as its further implication on the research and development area. These two segmentations are also discussed in detail for the given period. The market is segmented by region into the North America, Europe, Asia-Pacific, and ROW. Companies profiled in this report include Pfizer, Novartis, Shire Pharmaceuticals, Allergan plc, Barr Pharmaceuticals, and Cephalon.
REPORT INCLUDES
Increasing use of cognition drugs is the major factor that drives the global cognition and memoryenhancing drugs market. Cognition drugs play a crucial role in the treatment of cognitively impaired patients. Neurodegeneration is the major concern faced by people in various regions of the world, and it is also the major factor responsible causing severe diseases in such patients. The intensification and rise in research and development is expected to drive growth of the cognition and memory-enhancing drugs market. The market is observing various launches of new products and improvement in existing technologies. The existing as well as new technologies are expected to increase the demand for
cognition and memory-enhancing drugs in the market. However, the major restricting aspect of the global cognition and memory-enhancing drugs market is the longer timelines associated with the cognition drugs. Ensuring efficacy as well as safety during use of cognition drugs will aid in overcoming the threat of adverse effects.
In this report, the cognition and memory-enhancing drugs market is studied through different perspectives. The market is analyzed through the products and their applications in the treatment of several chronic diseases.
The cognition and memory-enhancing drugs market is categorized into eight types based on products: Aricept, Exelon, Reminyl, Namenda, Adderall, Ritalin, Dexedrin, and other cognition drugs. The Namenda cognition drug registered a revenue of REDACTED in 2016 and is poised to increase at a compound annual growth rate (CAGR) of REDACTED throughout the forecast period; this revenue is projected to reach REDACTED by 2022. Demand for Namenda is significant in the treatment of cognitively impaired patients. Additionally, this drug has gained immense traction in recent years among the youth.
The global cognition and memory-enhancing drugs market based on applications is segmented in four categories: Alzheimer’s disease, education industry, sports, and other applications. The Alzheimer’s disease segment has dominated the global cognition and memory-enhancing drugs market and is anticipated to do so during the forecast period. This segment accounted for a revenue of REDACTED in 2016, registering a CAGR of REDACTED; this revenue is expected to reach REDACTED by 2022. However, the use of cognition products in sports applications has increased in recent years. The sports sector has registered a CAGR of REDACTED, indicating a rapid growth among all the other applications.
By geography, the global cognition and memory-enhancing drugs market is divided into North America, Europe, Asia-Pacific, and the Rest of World (ROW). North America held the largest market share in 2016 and accounted for REDACTED, growing at the CAGR of REDACTED during the analysis period. It is anticipated that market will reach REDACTED by 2022. In North America, the U.S. leads the market due to surging demand for cognition products as well as memory enhancers in the treatment of Alzheimer’s disease. Asia-Pacific held the second-largest market share for the cognition and memory-enhancing drugs market globally; it accounted for REDACTED in 2016 and is expected to reach REDACTED by 2022 at a CAGR of REDACTED. Japan is leading the cognition and memory-enhancing drugs market in the Asia-Pacific region, and the growth of this market is supplemented by increasing government initiatives to encourage production of cognition drugs as well as focusing on brain fitness. Asia-Pacific is a lucrative market for cognition drugs. The majority of the markets in Asia-Pacific and ROW regions are untapped and hence provide opportunities for cognition drugs manufacturers to expand their business.
This research report presents an in-depth analysis of the global cognition and memory-enhancing drugs market by application, product categories, and regional markets. The report includes key cognition drugs that are incorporated in several therapeutic treatment methods. It discusses the role of supply chain members from manufacturers to researchers. The report has an in-depth analysis of key companies operating in the global cognition and memory-enhancing drugs market. In-depth patent analysis in the report will focus on providing extensive technological trends across years and regions such as the U.S., Europe, and China.
The cognition and memory-enhancing drugs market is segmented mainly into eight components: Aricept, Exelon, Reminyl, Namenda, Adderall, Ritalin, Dexedrin, and other cognition drugs. This market is further segmented on the basis of applications, which helps in understanding the potency of these memory enhancers in several therapeutic treatments. The market study is detailed for products based on applications as well as its further implication on the research and development area. These two segmentations are also discussed in detail for the given period. The market is segmented by region into the North America, Europe, Asia-Pacific, and ROW. Companies profiled in this report include Pfizer, Novartis, Shire Pharmaceuticals, Allergan plc, Barr Pharmaceuticals, and Cephalon.
REPORT INCLUDES
- 34 data tables and 14 additional tables
- An overview of the global market for cognition and memory enhancement drugs
- Analyses of global market trends, with data from 2016 to 2017, and projections of compound annual growth rates (CAGRs) through 2022
- An overview of the ethics and side effects of cognition and memory enhancement drugs
- Market analyses by application, product, and region
- Assessment of patent litigation claims
- Insight into the competitive landscape, including mergers and acquisitions and new product launches
- Profiles of key companies in the market, including Pfizer, Novartis, Shire Pharmaceuticals, Allergan Plc, Barr Pharmaceuticals, and Cephalon
Increasing use of cognition drugs is the major factor that drives the global cognition and memoryenhancing drugs market. Cognition drugs play a crucial role in the treatment of cognitively impaired patients. Neurodegeneration is the major concern faced by people in various regions of the world, and it is also the major factor responsible causing severe diseases in such patients. The intensification and rise in research and development is expected to drive growth of the cognition and memory-enhancing drugs market. The market is observing various launches of new products and improvement in existing technologies. The existing as well as new technologies are expected to increase the demand for
cognition and memory-enhancing drugs in the market. However, the major restricting aspect of the global cognition and memory-enhancing drugs market is the longer timelines associated with the cognition drugs. Ensuring efficacy as well as safety during use of cognition drugs will aid in overcoming the threat of adverse effects.
In this report, the cognition and memory-enhancing drugs market is studied through different perspectives. The market is analyzed through the products and their applications in the treatment of several chronic diseases.
The cognition and memory-enhancing drugs market is categorized into eight types based on products: Aricept, Exelon, Reminyl, Namenda, Adderall, Ritalin, Dexedrin, and other cognition drugs. The Namenda cognition drug registered a revenue of REDACTED in 2016 and is poised to increase at a compound annual growth rate (CAGR) of REDACTED throughout the forecast period; this revenue is projected to reach REDACTED by 2022. Demand for Namenda is significant in the treatment of cognitively impaired patients. Additionally, this drug has gained immense traction in recent years among the youth.
The global cognition and memory-enhancing drugs market based on applications is segmented in four categories: Alzheimer’s disease, education industry, sports, and other applications. The Alzheimer’s disease segment has dominated the global cognition and memory-enhancing drugs market and is anticipated to do so during the forecast period. This segment accounted for a revenue of REDACTED in 2016, registering a CAGR of REDACTED; this revenue is expected to reach REDACTED by 2022. However, the use of cognition products in sports applications has increased in recent years. The sports sector has registered a CAGR of REDACTED, indicating a rapid growth among all the other applications.
By geography, the global cognition and memory-enhancing drugs market is divided into North America, Europe, Asia-Pacific, and the Rest of World (ROW). North America held the largest market share in 2016 and accounted for REDACTED, growing at the CAGR of REDACTED during the analysis period. It is anticipated that market will reach REDACTED by 2022. In North America, the U.S. leads the market due to surging demand for cognition products as well as memory enhancers in the treatment of Alzheimer’s disease. Asia-Pacific held the second-largest market share for the cognition and memory-enhancing drugs market globally; it accounted for REDACTED in 2016 and is expected to reach REDACTED by 2022 at a CAGR of REDACTED. Japan is leading the cognition and memory-enhancing drugs market in the Asia-Pacific region, and the growth of this market is supplemented by increasing government initiatives to encourage production of cognition drugs as well as focusing on brain fitness. Asia-Pacific is a lucrative market for cognition drugs. The majority of the markets in Asia-Pacific and ROW regions are untapped and hence provide opportunities for cognition drugs manufacturers to expand their business.
CHAPTER 1 INTRODUCTION
Study Goals and Objectives
Reasons for Doing This Study
Scope of Report
Information Sources and Methodology
Intended Audience
Geographic Breakdown
Analyst's Credentials
Related BCC Research Reports
CHAPTER 2 SUMMARY AND HIGHLIGHTS
CHAPTER 3 MARKET AND TECHNOLOGY BACKGROUND
Market Definition
Ethics and Cognition and Memory-enhancing Drugs
Treatments Available for Dementia
Cholinesterase Inhibitors
Memantine
Nondrug Treatments for Dementia
Availability of Dementia Treatments
Treatment for Other Symptoms of Dementia Including Aggression and Anxiety
Side Effects of Cognition and Memory-enhancing Drugs
Benefits and Side Effects of Consuming Cognition Drugs
Guidance Given by the American Academy of Neurology
Current Cognition Enhancers
Physical Exercise
Diet and Nutrition
Social Engagement
Sleep
Computer Training Programs
ADHD Drugs, Symptoms, and Side Effects
Use of Pharmacological Cognitive Enhancers by Healthy Individuals
Enhancement of Executive Functions
Use of Cannabis in Adolescence
Use of Illicit and Prescription Drugs for Cognitive or Mood Enhancement Among Surgeons
Study Reported in BMC Medicine in 2013 and Other Studies
Executive Functions
Working Memory
Neuropsychiatric Disorders
Enhancer Drug Use Trends Among Youth
Future Prediction of Social Acceptance of Cognition and Memory-enhancing Drugs
Patent Litigation Claims in the Cognition and Memory-enhancing Drugs Market
Different Patent Infringement Types
Clinical Guidelines
Clinical Guidelines for Cognitive and Behavioral Problems in Dementia
Clinical Practice Guidelines for Dementia in Australia
Technology Trends
Recent Studies Highlighting Potential of Cognition Drugs in Chess
Market Dynamics
Drivers
Restraints
Opportunities
CHAPTER 4 GLOBAL COGNITION AND MEMORY-ENHANCING DRUGS MARKET BREAKDOWN BY PRODUCT TYPE
ADHD, Attention Deficit Hyperactivity Disorder; MPH, Methylphenidate
Prohibition of Cognition Enhancers in Healthy Individuals
Global Cognition and Memory-enhancing Drugs Market
Aricept
Exelon
Reminyl
Namenda
Adderall
Ritalin
Dexedrin
Other Cognition and Memory-Enhancing Products
CHAPTER 5 GLOBAL COGNITION AND MEMORY-ENHANCING DRUGS MARKET BREAKDOWN BY APPLICATION
Alzheimer's Disease
Brain Changes Associated with Alzheimer's Disease
Mild Cognitive Impairment (MCI) - A Potential Precursor to Alzheimer’s and Other Dementias
Recent Case Study on Alzheimer's Disease Drug: 2017
Case Study on Alzheimer's Disease Drug: 2015
Mortality and Morbidity Because of Alzheimer's Disease
Healthcare Expenditure on Alzheimer's Disease
Emergence of Biomarkers as Diagnostic Tool for Alzheimer's Disease
Alzheimer's Disease Facts
Difference between Alzheimer's Disease and Dementia
Susceptibility Factors for Alzheimer's Disease
Causes of Alzheimer's Disease
Diagnosis of Alzheimer's Disease
Screening of Other Health Conditions of People Suffering from Alzheimer's Disease
Importance of Comprehensive Clinical Evaluation in the Case of Alzheimer's Disease Patients
Education Sector
Sports
Other Applications
Cognitive Impairment in People Suffering from Parkinson's Disease
Treatment of Parkinson's Disease Dementia
Cognitive Decline in Patients Suffering from Parkinson's Disease Causing Further Complexities
CHAPTER 6 GLOBAL COGNITION AND MEMORY-ENHANCING DRUGS MARKET BREAKDOWN BY REGION
North America
U.S.
Canada
Mexico
Europe
U.K.
Germany
France
Rest of Europe
Asia-Pacific
China
Japan
Australia
India
Rest of Asia
ROW
Brazil
Turkey
South Africa
CHAPTER 7 PATENT REVIEW
Patent Analysis
Patents Filed in Asia-Pacific
Patents Filed in North America
CHAPTER 8 ANALYSIS OF MARKET OPPORTUNITIES
Product Approval
Business Collaboration
CHAPTER 9 COMPANY PROFILES
ACCELERATED INTELLIGENCE INC.
Overview
Products
ALLERGAN PLC
Overview
Products
ALTERNASCRIPT LLC
Overview
Products
CAMBRIDGE COGNITION
Overview
Products
CERETROPIC
Overview
Products
COGNITION THERAPEUTICS INC.
Overview
Products
COGSTATE LTD.
Overview
Products
HVMN
Overview
Products
NOOTRIMENT
Overview
Products
NOVARTIS AG
Overview
ONNIT LABS LLC
Overview
Products
PEAK NOOTROPICS
Overview
Products
PFIZER INC.
Overview
Products
PURELIFE BIOSCIENCE CO., LTD.
Overview
Products
SHIRE
Overview
Products
SUPNOOTROPIC BIO CO., LTD.
Overview
Products
TEVA PHARMACEUTICALS INDUSTRIES LTD. (BARR PHARMACEUTICALS)
Overview
Products
CHAPTER 10 APPENDIX: PATENTS, DRUGS AND COGNITIVE ENHANCERS
List of Patents North America
List of Patents Applied Globally
List of Drugs and Cognitive Enhancers
1,3-Dimethylamylamine
5-HTP
Acetyl L-Carnitine
Adrafinil
Agmatine
Alpha-GPC
Alpha-Lipoic Acid
Aniracetam
Bacopa Monnieri
Blueberry
Boswellia Serrata
Caffeine
CDP-Choline
Celastrus Paniculatus
Clitoria Ternatea (Shanka Pushpi)
Cocoa Flavanols
Coluracetam
Convolvulus Pluricaulis (Shankhapushpi)
Creatine
D-Serine
Dehydroepiandrosterone
Dimocarpus Longan
Emblica Officinalis (Amla)
Fish Oil (DHA, EPA, Omega-3)
GABA
Ginkgo biloba
Glycine
Gotu Kola (Centella Asiatica)
Grape Seed Extract
Green Tea Catechins
Hordenine
Huperzine-A
Idebenone
Kava
Krill Oil
L-DOPA
L-Tyrosine
Magnolia Officinalis
Melissa Officinalis (Lemon Balm)
Modafinil
Morus Alba
Mucuna Pruriens
Muira Puama
Nardostachys Jatamansi
Nefiracetam
Nicotine
Nigella Sativa
Noopept
Oxiracetam
Panax Ginseng
Phenylethylamine
Phenylpiracetam
Phosphatidylserine
Piracetam
Polygala Tenuifolia
Pramiracetam
PRL-8-53
Pueraria Lobata
Pycnogenol
Pyritinol
Resveratrol
Rhodiola Rosea
S-Adenosyl Methionine
Sarcosine
Scutellaria baicalensis
Sulbutiamine
Sunifiram
Theanine
Uridine
Vinpocetine
Vitamin B12
Yamabushitake
Yerba Mate
Zinc
Study Goals and Objectives
Reasons for Doing This Study
Scope of Report
Information Sources and Methodology
Intended Audience
Geographic Breakdown
Analyst's Credentials
Related BCC Research Reports
CHAPTER 2 SUMMARY AND HIGHLIGHTS
CHAPTER 3 MARKET AND TECHNOLOGY BACKGROUND
Market Definition
Ethics and Cognition and Memory-enhancing Drugs
Treatments Available for Dementia
Cholinesterase Inhibitors
Memantine
Nondrug Treatments for Dementia
Availability of Dementia Treatments
Treatment for Other Symptoms of Dementia Including Aggression and Anxiety
Side Effects of Cognition and Memory-enhancing Drugs
Benefits and Side Effects of Consuming Cognition Drugs
Guidance Given by the American Academy of Neurology
Current Cognition Enhancers
Physical Exercise
Diet and Nutrition
Social Engagement
Sleep
Computer Training Programs
ADHD Drugs, Symptoms, and Side Effects
Use of Pharmacological Cognitive Enhancers by Healthy Individuals
Enhancement of Executive Functions
Use of Cannabis in Adolescence
Use of Illicit and Prescription Drugs for Cognitive or Mood Enhancement Among Surgeons
Study Reported in BMC Medicine in 2013 and Other Studies
Executive Functions
Working Memory
Neuropsychiatric Disorders
Enhancer Drug Use Trends Among Youth
Future Prediction of Social Acceptance of Cognition and Memory-enhancing Drugs
Patent Litigation Claims in the Cognition and Memory-enhancing Drugs Market
Different Patent Infringement Types
Clinical Guidelines
Clinical Guidelines for Cognitive and Behavioral Problems in Dementia
Clinical Practice Guidelines for Dementia in Australia
Technology Trends
Recent Studies Highlighting Potential of Cognition Drugs in Chess
Market Dynamics
Drivers
Restraints
Opportunities
CHAPTER 4 GLOBAL COGNITION AND MEMORY-ENHANCING DRUGS MARKET BREAKDOWN BY PRODUCT TYPE
ADHD, Attention Deficit Hyperactivity Disorder; MPH, Methylphenidate
Prohibition of Cognition Enhancers in Healthy Individuals
Global Cognition and Memory-enhancing Drugs Market
Aricept
Exelon
Reminyl
Namenda
Adderall
Ritalin
Dexedrin
Other Cognition and Memory-Enhancing Products
CHAPTER 5 GLOBAL COGNITION AND MEMORY-ENHANCING DRUGS MARKET BREAKDOWN BY APPLICATION
Alzheimer's Disease
Brain Changes Associated with Alzheimer's Disease
Mild Cognitive Impairment (MCI) - A Potential Precursor to Alzheimer’s and Other Dementias
Recent Case Study on Alzheimer's Disease Drug: 2017
Case Study on Alzheimer's Disease Drug: 2015
Mortality and Morbidity Because of Alzheimer's Disease
Healthcare Expenditure on Alzheimer's Disease
Emergence of Biomarkers as Diagnostic Tool for Alzheimer's Disease
Alzheimer's Disease Facts
Difference between Alzheimer's Disease and Dementia
Susceptibility Factors for Alzheimer's Disease
Causes of Alzheimer's Disease
Diagnosis of Alzheimer's Disease
Screening of Other Health Conditions of People Suffering from Alzheimer's Disease
Importance of Comprehensive Clinical Evaluation in the Case of Alzheimer's Disease Patients
Education Sector
Sports
Other Applications
Cognitive Impairment in People Suffering from Parkinson's Disease
Treatment of Parkinson's Disease Dementia
Cognitive Decline in Patients Suffering from Parkinson's Disease Causing Further Complexities
CHAPTER 6 GLOBAL COGNITION AND MEMORY-ENHANCING DRUGS MARKET BREAKDOWN BY REGION
North America
U.S.
Canada
Mexico
Europe
U.K.
Germany
France
Rest of Europe
Asia-Pacific
China
Japan
Australia
India
Rest of Asia
ROW
Brazil
Turkey
South Africa
CHAPTER 7 PATENT REVIEW
Patent Analysis
Patents Filed in Asia-Pacific
Patents Filed in North America
CHAPTER 8 ANALYSIS OF MARKET OPPORTUNITIES
Product Approval
Business Collaboration
CHAPTER 9 COMPANY PROFILES
ACCELERATED INTELLIGENCE INC.
Overview
Products
ALLERGAN PLC
Overview
Products
ALTERNASCRIPT LLC
Overview
Products
CAMBRIDGE COGNITION
Overview
Products
CERETROPIC
Overview
Products
COGNITION THERAPEUTICS INC.
Overview
Products
COGSTATE LTD.
Overview
Products
HVMN
Overview
Products
NOOTRIMENT
Overview
Products
NOVARTIS AG
Overview
ONNIT LABS LLC
Overview
Products
PEAK NOOTROPICS
Overview
Products
PFIZER INC.
Overview
Products
PURELIFE BIOSCIENCE CO., LTD.
Overview
Products
SHIRE
Overview
Products
SUPNOOTROPIC BIO CO., LTD.
Overview
Products
TEVA PHARMACEUTICALS INDUSTRIES LTD. (BARR PHARMACEUTICALS)
Overview
Products
CHAPTER 10 APPENDIX: PATENTS, DRUGS AND COGNITIVE ENHANCERS
List of Patents North America
List of Patents Applied Globally
List of Drugs and Cognitive Enhancers
1,3-Dimethylamylamine
5-HTP
Acetyl L-Carnitine
Adrafinil
Agmatine
Alpha-GPC
Alpha-Lipoic Acid
Aniracetam
Bacopa Monnieri
Blueberry
Boswellia Serrata
Caffeine
CDP-Choline
Celastrus Paniculatus
Clitoria Ternatea (Shanka Pushpi)
Cocoa Flavanols
Coluracetam
Convolvulus Pluricaulis (Shankhapushpi)
Creatine
D-Serine
Dehydroepiandrosterone
Dimocarpus Longan
Emblica Officinalis (Amla)
Fish Oil (DHA, EPA, Omega-3)
GABA
Ginkgo biloba
Glycine
Gotu Kola (Centella Asiatica)
Grape Seed Extract
Green Tea Catechins
Hordenine
Huperzine-A
Idebenone
Kava
Krill Oil
L-DOPA
L-Tyrosine
Magnolia Officinalis
Melissa Officinalis (Lemon Balm)
Modafinil
Morus Alba
Mucuna Pruriens
Muira Puama
Nardostachys Jatamansi
Nefiracetam
Nicotine
Nigella Sativa
Noopept
Oxiracetam
Panax Ginseng
Phenylethylamine
Phenylpiracetam
Phosphatidylserine
Piracetam
Polygala Tenuifolia
Pramiracetam
PRL-8-53
Pueraria Lobata
Pycnogenol
Pyritinol
Resveratrol
Rhodiola Rosea
S-Adenosyl Methionine
Sarcosine
Scutellaria baicalensis
Sulbutiamine
Sunifiram
Theanine
Uridine
Vinpocetine
Vitamin B12
Yamabushitake
Yerba Mate
Zinc
LIST OF TABLES
Summary Table: Global Market for Cognition and Memory-enhancing Drugs, by Region, Through 2022
Table 1: Key Trends in Global Cognition Drugs and Memory Enhancers
Table 2: Drugs Used to Enhance Cognitive Function
Table 3: Global Market for Cognition and Memory-enhancing Drugs, by Product, Through 2022
Table 4: Global Market for Aricept, by Region, Through 2022
Table 5: Global Market for Exelon, by Region, Through 2022
Table 6: Administration of Exelon
Table 7: Global Market for Reminyl, by Region, Through 2022
Table 8: Companies Manufacturing Reminyl
Table 9: Global Market for Namenda, by Region, Through 2022
Table 10: Global Market for Adderall, by Region, Through 2022
Table 11: Global Market for Ritalin, by Region, Through 2022
Table 12: Global Market for Dexedrin, by Region, Through 2022
Table 13: Global Market for Other Cognition and Memory-enhancing Drugs, by Region, Through 2022
Table 14: Causes of Dementia and Associated Characteristics
Table 15: Global Market for Cognition and Memory-enhancing Drugs, by Application, Through 2022
Table 16: Global Cognition and Memory-enhancing Drugs Market for Alzheimer’s Disease, by Region, Through 2022
Table 17: Causes of Dementia and Associated Characteristics
Table 18: Global Cognition and Memory-enhancing Drugs Market in the Education Sector, by Region, Through 2022
Table 19: Global Cognition and Memory-enhancing Drugs Market in Sports, by Region, Through 2022
Table 20: Global Cognition and Memory-enhancing Drugs Market in Other Applications, by Region, Through 2022
Table 21: Global Market for Cognition and Memory-enhancing Drugs, by Region, Through 2022
Table 22: North American Market for Cognition and Memory-enhancing Drugs, by Country, Through 2022
Table 23: North American Market for Cognition and Memory-enhancing Drugs, by Product, Through 2022
Table 24: North American Market for Cognition and Memory-enhancing Drugs, by Application, Through 2022
Table 25: European Market for Cognition and Memory-enhancing Drugs, by Country, Through 2022
Table 26: European Market for Cognition and Memory-enhancing Drugs, by Product, Through 2022
Table 27: European Market for Cognition and Memory-enhancing Drugs, by Application, Through 2022
Table 28: Asia-Pacific Market for Cognition and Memory-enhancing Drugs, by Country, Through 2022
Table 29: Asia-Pacific Market for Cognition and Memory-enhancing Drugs, by Product, Through 2022
Table 30: Asia-Pacific Market for Cognition and Memory-enhancing Drugs, by Application, Through 2022
Table 31: Rest of the World Market for Cognition and Memory-enhancing Drugs, by Country, Through 2022
Table 32: Rest of the World Market for Cognition and Memory-enhancing Drugs, by Product, Through 2022
Table 33: Rest of the World Market for Cognition and Memory-enhancing Drugs, by Application, Through 2022
Table 34: Patent Review of Cognition Drugs Market, 2013-2016
Table 35: Patent Review of Cognition Drugs Market, by Region, 2013-2016
Table 36: Allergan’s Financials, 2014-2016
Table 37: Allergan’s Developments, 2014-2017
Table 38: Cognition Therapeutics' Developments, 2014-2017
Table 39: Novartis’ Financials, 2014-2016
Table 40: Novartis’ Developments, 2014-2017
Table 41: Pfizer’s Financials, 2014-2016
Table 42: Pfizer’s Developments, 2014-2017
Table 43: Shire’s Financials, 2014-2016
Table 44: Teva’s Financials, 2014-2016
Table 45: Teva’s Developments, 2014-2017
Table 46: List of Patents, North America
Table 47: List of Patents Applied Globally
Summary Table: Global Market for Cognition and Memory-enhancing Drugs, by Region, Through 2022
Table 1: Key Trends in Global Cognition Drugs and Memory Enhancers
Table 2: Drugs Used to Enhance Cognitive Function
Table 3: Global Market for Cognition and Memory-enhancing Drugs, by Product, Through 2022
Table 4: Global Market for Aricept, by Region, Through 2022
Table 5: Global Market for Exelon, by Region, Through 2022
Table 6: Administration of Exelon
Table 7: Global Market for Reminyl, by Region, Through 2022
Table 8: Companies Manufacturing Reminyl
Table 9: Global Market for Namenda, by Region, Through 2022
Table 10: Global Market for Adderall, by Region, Through 2022
Table 11: Global Market for Ritalin, by Region, Through 2022
Table 12: Global Market for Dexedrin, by Region, Through 2022
Table 13: Global Market for Other Cognition and Memory-enhancing Drugs, by Region, Through 2022
Table 14: Causes of Dementia and Associated Characteristics
Table 15: Global Market for Cognition and Memory-enhancing Drugs, by Application, Through 2022
Table 16: Global Cognition and Memory-enhancing Drugs Market for Alzheimer’s Disease, by Region, Through 2022
Table 17: Causes of Dementia and Associated Characteristics
Table 18: Global Cognition and Memory-enhancing Drugs Market in the Education Sector, by Region, Through 2022
Table 19: Global Cognition and Memory-enhancing Drugs Market in Sports, by Region, Through 2022
Table 20: Global Cognition and Memory-enhancing Drugs Market in Other Applications, by Region, Through 2022
Table 21: Global Market for Cognition and Memory-enhancing Drugs, by Region, Through 2022
Table 22: North American Market for Cognition and Memory-enhancing Drugs, by Country, Through 2022
Table 23: North American Market for Cognition and Memory-enhancing Drugs, by Product, Through 2022
Table 24: North American Market for Cognition and Memory-enhancing Drugs, by Application, Through 2022
Table 25: European Market for Cognition and Memory-enhancing Drugs, by Country, Through 2022
Table 26: European Market for Cognition and Memory-enhancing Drugs, by Product, Through 2022
Table 27: European Market for Cognition and Memory-enhancing Drugs, by Application, Through 2022
Table 28: Asia-Pacific Market for Cognition and Memory-enhancing Drugs, by Country, Through 2022
Table 29: Asia-Pacific Market for Cognition and Memory-enhancing Drugs, by Product, Through 2022
Table 30: Asia-Pacific Market for Cognition and Memory-enhancing Drugs, by Application, Through 2022
Table 31: Rest of the World Market for Cognition and Memory-enhancing Drugs, by Country, Through 2022
Table 32: Rest of the World Market for Cognition and Memory-enhancing Drugs, by Product, Through 2022
Table 33: Rest of the World Market for Cognition and Memory-enhancing Drugs, by Application, Through 2022
Table 34: Patent Review of Cognition Drugs Market, 2013-2016
Table 35: Patent Review of Cognition Drugs Market, by Region, 2013-2016
Table 36: Allergan’s Financials, 2014-2016
Table 37: Allergan’s Developments, 2014-2017
Table 38: Cognition Therapeutics' Developments, 2014-2017
Table 39: Novartis’ Financials, 2014-2016
Table 40: Novartis’ Developments, 2014-2017
Table 41: Pfizer’s Financials, 2014-2016
Table 42: Pfizer’s Developments, 2014-2017
Table 43: Shire’s Financials, 2014-2016
Table 44: Teva’s Financials, 2014-2016
Table 45: Teva’s Developments, 2014-2017
Table 46: List of Patents, North America
Table 47: List of Patents Applied Globally
LIST OF FIGURES
Summary Figure: Global Market for Cognition and Memory-enhancing Drugs, by Region, 2016-2022
Figure 1: Medication Overdose: Cognitive Impairment
Figure 2: Acetylcholinesterase Inhibitor Used in the Alzheimer’s Disease Management
Figure 3: Role of Modafinil in the Management of Alzheimer’s Disease
Figure 4: Off-license use of Pharmacological Cognitive-Enhancing Drugs
Figure 5: Risk Associated with the Excessive Use of Cannabis
Figure 6: Role of Adolescence in the Cognition Process
Figure 7: Statistical Analysis of Aging Population in the U.S.
Figure 8: Global Market Segmentation for Cognition and Memory-enhancing Drugs, by Type
Figure 9: Global Market for Cognition and Memory-enhancing Drugs, by Application
Figure 10: The Stages of Alzheimer’s Disease
Figure 11: The Stages of Parkinson’s Disease
Figure 12: U.S. Market for Cognition and Memory-enhancing Drugs, 2016-2022
Figure 13: Canadian Market for Cognition and Memory-enhancing Drugs, 2016-2022
Figure 14: Mexican Market for Cognition and Memory-enhancing Drugs, 2016-2022
Figure 15: U.K. Market for Cognition and Memory-enhancing Drugs, 2016-2022
Figure 16: German Market for Cognition and Memory-enhancing Drugs, 2016-2022
Figure 17: French Market for Cognition and Memory-enhancing Drugs, 2016-2022
Figure 18: Rest of Europe Market for Cognition and Memory-enhancing Drugs, 2016-2022
Figure 19: Chinese Market for Cognition and Memory-enhancing Drugs, 2016-2022
Figure 20: Japanese Market for Cognition and Memory-enhancing Drugs, 2016-2022
Figure 21: Australian Market for Cognition and Memory-enhancing Drugs, 2016-2022
Figure 22: Indian Market for Cognition and Memory-enhancing Drugs, 2016-2022
Figure 23: Rest of Asia-Pacific Market for Cognition and Memory-enhancing Drugs, 2016-2022
Figure 24: Brazilian Market for Cognition and Memory-enhancing Drugs, 2016-2022
Figure 25: Turkey’s Market for Cognition and Memory-enhancing Drugs, 2016-2022
Figure 26: South African Market for Cognition and Memory-enhancing Drugs, 2016-2022
Figure 27: Strategies for Global Cognition and Memory-enhancing Drugs Market, 2014-2017
Figure 28: Market Players Adopting Several Strategies for Global Cognition and Memory-enhancing Drugs Market, 2014-2017
Summary Figure: Global Market for Cognition and Memory-enhancing Drugs, by Region, 2016-2022
Figure 1: Medication Overdose: Cognitive Impairment
Figure 2: Acetylcholinesterase Inhibitor Used in the Alzheimer’s Disease Management
Figure 3: Role of Modafinil in the Management of Alzheimer’s Disease
Figure 4: Off-license use of Pharmacological Cognitive-Enhancing Drugs
Figure 5: Risk Associated with the Excessive Use of Cannabis
Figure 6: Role of Adolescence in the Cognition Process
Figure 7: Statistical Analysis of Aging Population in the U.S.
Figure 8: Global Market Segmentation for Cognition and Memory-enhancing Drugs, by Type
Figure 9: Global Market for Cognition and Memory-enhancing Drugs, by Application
Figure 10: The Stages of Alzheimer’s Disease
Figure 11: The Stages of Parkinson’s Disease
Figure 12: U.S. Market for Cognition and Memory-enhancing Drugs, 2016-2022
Figure 13: Canadian Market for Cognition and Memory-enhancing Drugs, 2016-2022
Figure 14: Mexican Market for Cognition and Memory-enhancing Drugs, 2016-2022
Figure 15: U.K. Market for Cognition and Memory-enhancing Drugs, 2016-2022
Figure 16: German Market for Cognition and Memory-enhancing Drugs, 2016-2022
Figure 17: French Market for Cognition and Memory-enhancing Drugs, 2016-2022
Figure 18: Rest of Europe Market for Cognition and Memory-enhancing Drugs, 2016-2022
Figure 19: Chinese Market for Cognition and Memory-enhancing Drugs, 2016-2022
Figure 20: Japanese Market for Cognition and Memory-enhancing Drugs, 2016-2022
Figure 21: Australian Market for Cognition and Memory-enhancing Drugs, 2016-2022
Figure 22: Indian Market for Cognition and Memory-enhancing Drugs, 2016-2022
Figure 23: Rest of Asia-Pacific Market for Cognition and Memory-enhancing Drugs, 2016-2022
Figure 24: Brazilian Market for Cognition and Memory-enhancing Drugs, 2016-2022
Figure 25: Turkey’s Market for Cognition and Memory-enhancing Drugs, 2016-2022
Figure 26: South African Market for Cognition and Memory-enhancing Drugs, 2016-2022
Figure 27: Strategies for Global Cognition and Memory-enhancing Drugs Market, 2014-2017
Figure 28: Market Players Adopting Several Strategies for Global Cognition and Memory-enhancing Drugs Market, 2014-2017
